SNCE - Baird sees 60% upside in healthcare tech 'ignited' by COVID-19

Baird has started coverage with a Street-high price target on a healthcare tech firm whose time may have come alongside the COVID-19 pandemic. COVID "ignited" decentralized clinical trial solutions, or DCT, analyst Eric Coldwell writes, and "we see no turning back." And the clear leader in DCT is Science 37 Holdings (NASDAQ:SNCE), the firm says. "At its most basic, DCT is a patient-centric approach, leveraging technology and high-touch services to reduce burdens and barriers associated with traditional site-based trial design," Baird says. Its concepts have gradually seeped into study design, but COVID provided an accelerant. Science 37 is a pioneer there, founded in 2014 but finding its moment now not only with "pandemic realities" but also a management change. The company is pushing a flexible model that has the ability to run virtual trials end to end; to act as a single "metasite" alongside traditional brick-and-mortar sites; or provide point

For further details see:

Baird sees 60% upside in healthcare tech 'ignited' by COVID-19